VEGFA and hereditary hemorrhagic telangiectasia: Both bevacizumab, an antiangiogenic monoclonal antibody that selectively targets Vascular Endothelial Growth Factor (VEGF) (13), and thalidomide, a potent immunosuppressive and antiangiogenic agent (14) could be used to treat HHT patient hemorrhages but with long-term side effects (15).